vasopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vasopressin analogues 2810 113-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vasopressin
  • 8-L-arginine vasopressin
  • synthetic vasopressin
  • 8-L-Arginine-vasopressin
  • argipressin
  • vasopressin tannate
  • vasopressin injection
  • antidiuretic hormone
  • pitressin tannate
  • Molecular weight: 1084.24
  • Formula: C46H65N15O12S2
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 27
  • HDO: 15
  • TPSA: 461.43
  • ALOGS: -3.93
  • ROTB: 19
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 U P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC 16
kinase-selectivity-class GRK2,PDK1 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.479 High 0.89
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 464.97 36.72 553 6636 1383745 89237513
Intentional overdose 312.39 36.72 151 7038 93683 90527575
Lactic acidosis 223.24 36.72 99 7090 50364 90570894
Metabolic acidosis 189.26 36.72 91 7098 55585 90565673
Vitamin B1 decreased 173.34 36.72 31 7158 507 90620751
Cardiogenic shock 172.52 36.72 67 7122 24401 90596857
Hypotension 168.27 36.72 165 7024 325232 90296026
Toxicity to various agents 163.99 36.72 154 7035 287692 90333566
Cardiac arrest 162.53 36.72 102 7087 104833 90516425
Acute respiratory distress syndrome 162.20 36.72 67 7122 28619 90592639
Multiple organ dysfunction syndrome 160.37 36.72 87 7102 68249 90553009
Blood lactic acid decreased 159.21 36.72 28 7161 414 90620844
Shock 158.61 36.72 66 7123 28712 90592546
Hyperlactacidaemia 157.39 36.72 41 7148 4095 90617163
Cardiac output increased 147.29 36.72 27 7162 510 90620748
Distributive shock 120.95 36.72 32 7157 3392 90617866
Septic shock 118.31 36.72 77 7112 84083 90537175
Acute kidney injury 110.02 36.72 131 7058 320256 90301002
Vasoplegia syndrome 107.57 36.72 28 7161 2786 90618472
Hypoxia 106.08 36.72 68 7121 72331 90548927
Pulseless electrical activity 90.71 36.72 32 7157 8900 90612358
Vitamin B1 increased 89.39 36.72 15 7174 165 90621093
Electrocardiogram abnormal 75.39 36.72 29 7160 10269 90610989
Drug ineffective for unapproved indication 70.03 36.72 51 7138 66593 90554665
Analgesic therapy 69.67 36.72 15 7174 657 90620601
Tachycardia 68.55 36.72 73 7116 157600 90463658
Antacid therapy 67.95 36.72 15 7174 739 90620519
Appendicolith 67.81 36.72 15 7174 746 90620512
Anticoagulant therapy 66.75 36.72 15 7174 802 90620456
Disseminated intravascular coagulation 66.49 36.72 33 7156 21505 90599753
Peripheral ischaemia 64.08 36.72 22 7167 5645 90615613
Bradycardia 59.68 36.72 51 7138 83796 90537462
Diabetes insipidus 58.92 36.72 18 7171 3194 90618064
Extremity necrosis 58.34 36.72 16 7173 1941 90619317
Haemodynamic instability 58.23 36.72 25 7164 11714 90609544
Fatigue 57.69 36.72 11 7178 1154012 89467246
Respiratory failure 57.14 36.72 58 7131 118360 90502898
Hypoglycaemia 54.90 36.72 45 7144 69803 90551455
Electrocardiogram QRS complex prolonged 54.88 36.72 21 7168 7327 90613931
Overdose 54.81 36.72 65 7124 157644 90463614
Hypothermia 54.49 36.72 26 7163 15549 90605709
Coagulopathy 52.75 36.72 29 7160 23260 90597998
Pulmonary oedema 48.80 36.72 40 7149 62040 90559218
Circulatory collapse 48.26 36.72 28 7161 24876 90596382
Hyperphosphataemia 48.24 36.72 16 7173 3695 90617563
Suicide attempt 47.90 36.72 43 7146 75356 90545902
Dry gangrene 42.81 36.72 10 7179 635 90620623
Blood phosphorus increased 42.05 36.72 15 7174 4303 90616955
Arthralgia 41.98 36.72 6 7183 778516 89842742
Local anaesthetic systemic toxicity 41.18 36.72 14 7175 3486 90617772
Anuria 40.74 36.72 21 7168 14797 90606461
Activated partial thromboplastin time prolonged 39.91 36.72 17 7172 7808 90613450
Stress cardiomyopathy 39.85 36.72 20 7169 13335 90607923
Electrocardiogram QT prolonged 39.60 36.72 38 7151 72418 90548840
Headache 39.44 36.72 10 7179 862736 89758522
Ventricular tachycardia 38.12 36.72 24 7165 24684 90596574
Sepsis 37.76 36.72 58 7131 179756 90441502
Renal failure 37.48 36.72 49 7140 130958 90490300
Premature delivery 36.97 36.72 28 7161 38734 90582524
Rash 36.82 36.72 9 7180 796091 89825167

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 534.79 36.26 187 12657 13269 42595222
Cardiogenic shock 465.91 36.26 223 12621 35417 42573074
Appendicitis 464.01 36.26 189 12655 20424 42588067
Multiple organ dysfunction syndrome 456.63 36.26 311 12533 96724 42511767
Drug ineffective 405.45 36.26 694 12150 629503 41978988
Stress 351.01 36.26 198 12646 44014 42564477
Ventricular fibrillation 306.19 36.26 159 12685 29964 42578527
Ascites 300.61 36.26 196 12648 56482 42552009
Blood phosphorus increased 258.42 36.26 108 12736 12417 42596074
Abdominal distension 256.70 36.26 195 12649 71540 42536951
Sepsis 202.17 36.26 273 12571 199061 42409430
Myasthenia gravis 201.53 36.26 98 12746 16039 42592452
Hyponatraemia 199.80 36.26 196 12648 101266 42507225
Hyperphosphataemia 174.57 36.26 83 12761 12921 42595570
Blood uric acid increased 166.29 36.26 85 12759 15462 42593029
Blood cholesterol increased 150.21 36.26 96 12748 26645 42581846
General physical health deterioration 149.81 36.26 205 12639 151041 42457450
Diabetes insipidus 148.84 36.26 52 12792 3661 42604830
Incorrect route of product administration 138.36 36.26 88 12756 24217 42584274
Hypophosphataemia 137.38 36.26 83 12761 20862 42587629
Dry mouth 137.13 36.26 106 12738 39773 42568718
Iron deficiency 134.54 36.26 66 12778 10995 42597496
Sleep disorder therapy 127.38 36.26 55 12789 6839 42601652
Bacterial infection 127.36 36.26 88 12756 27791 42580700
Analgesic therapy 126.97 36.26 54 12790 6470 42602021
Neuralgia 121.98 36.26 83 12761 25564 42582927
Abdominal pain 111.66 36.26 203 12641 190268 42418223
Constipation 109.43 36.26 184 12660 162107 42446384
Diarrhoea 105.91 36.26 9 12835 460840 42147651
Vasoplegia syndrome 98.09 36.26 35 12809 2620 42605871
Condition aggravated 85.86 36.26 220 12624 260534 42347957
Activated partial thromboplastin time prolonged 79.26 36.26 53 12791 15850 42592641
Antacid therapy 78.59 36.26 35 12809 4682 42603809
Anticoagulant therapy 76.69 36.26 34 12810 4501 42603990
Diabetes mellitus 74.24 36.26 91 12753 59996 42548495
Intentional product misuse 73.67 36.26 92 12752 61808 42546683
Swelling 69.22 36.26 84 12760 54801 42553690
Fatigue 68.68 36.26 23 12821 435618 42172873
Sleep disorder 66.24 36.26 77 12767 48018 42560473
Dizziness 62.66 36.26 3 12841 249251 42359240
Drug ineffective for unapproved indication 62.06 36.26 73 12771 46090 42562401
Vomiting 61.32 36.26 209 12635 289514 42318977
Rash 59.34 36.26 7 12837 276947 42331544
End stage renal disease 59.02 36.26 45 12799 16513 42591978
Thrombosis 58.96 36.26 87 12757 68424 42540067
Chronic obstructive pulmonary disease 58.47 36.26 83 12761 63031 42545460
Aortic stenosis 58.20 36.26 35 12809 8710 42599781
Total lung capacity decreased 57.91 36.26 26 12818 3544 42604947
Shock 56.65 36.26 56 12788 29065 42579426
Bacteroides infection 55.64 36.26 23 12821 2564 42605927
Ulcer 54.93 36.26 43 12801 16398 42592093
Fall 52.60 36.26 5 12839 234515 42373976
Malaise 51.90 36.26 3 12841 212153 42396338
Lactic acidosis 51.81 36.26 66 12778 45195 42563296
Blood calcium increased 51.56 36.26 32 12812 8422 42600069
Metabolic acidosis 50.71 36.26 70 12774 51788 42556703
Off label use 49.82 36.26 345 12499 637990 41970501
Distributive shock 49.68 36.26 21 12823 2475 42606016
Intestinal ischaemia 48.49 36.26 32 12812 9356 42599135
Somnolence 48.30 36.26 121 12723 140984 42467507
Troponin increased 47.35 36.26 42 12802 19020 42589471
Lung opacity 45.81 36.26 26 12818 5811 42602680
Drug intolerance 44.79 36.26 84 12760 80340 42528151
Renal injury 42.94 36.26 33 12811 12247 42596244
Gout 42.14 36.26 47 12797 28008 42580483
Decreased appetite 41.04 36.26 5 12839 193132 42415359
Cardiac arrest 39.78 36.26 96 12748 109224 42499267
Blood test abnormal 39.36 36.26 32 12812 12874 42595617
Pulse absent 38.71 36.26 24 12820 6303 42602188
Compartment syndrome 38.12 36.26 19 12825 3270 42605221

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 828.45 33.57 1173 18738 1519367 109050021
Appendicolith 679.07 33.57 201 19710 14054 110555334
Cardiogenic shock 672.88 33.57 285 19626 57053 110512335
Multiple organ dysfunction syndrome 653.56 33.57 381 19530 151329 110418059
Appendicitis 549.97 33.57 203 19708 28261 110541127
Ventricular fibrillation 388.99 33.57 176 19735 41137 110528251
Ascites 357.09 33.57 217 19694 92591 110476797
Blood phosphorus increased 339.48 33.57 123 19788 16217 110553171
Stress 302.80 33.57 205 19706 105143 110464245
Sepsis 268.52 33.57 312 19599 327034 110242354
Intentional overdose 258.48 33.57 204 19707 132297 110437091
Hyperphosphataemia 248.51 33.57 98 19813 16283 110553105
Myasthenia gravis 239.03 33.57 103 19808 21408 110547980
Blood uric acid increased 229.14 33.57 100 19811 21429 110547959
Lactic acidosis 225.52 33.57 163 19748 92648 110476740
Abdominal distension 224.37 33.57 212 19699 174891 110394497
Vasoplegia syndrome 212.99 33.57 66 19845 5373 110564015
Diabetes insipidus 212.86 33.57 69 19842 6501 110562887
Hyponatraemia 206.55 33.57 224 19687 217429 110351959
Analgesic therapy 205.87 33.57 69 19842 7215 110562173
Metabolic acidosis 204.03 33.57 158 19753 99586 110469802
Shock 184.90 33.57 117 19794 53471 110515917
Sleep disorder therapy 173.11 33.57 61 19850 7410 110561978
Hypophosphataemia 168.46 33.57 93 19818 33089 110536299
Bacterial infection 165.06 33.57 103 19808 45933 110523455
Cardiac arrest 155.13 33.57 184 19727 196569 110372819
Acute respiratory distress syndrome 153.83 33.57 104 19807 53094 110516294
Iron deficiency 152.83 33.57 72 19839 18404 110550984
Distributive shock 147.53 33.57 51 19860 5853 110563535
Antacid therapy 147.29 33.57 50 19861 5434 110563954
Anticoagulant therapy 144.46 33.57 49 19862 5312 110564076
Hypotension 136.73 33.57 295 19616 523554 110045834
Vitamin B1 decreased 130.75 33.57 31 19880 908 110568480
Activated partial thromboplastin time prolonged 128.33 33.57 68 19843 22300 110547088
Blood lactic acid decreased 128.30 33.57 28 19883 560 110568828
Cardiac output increased 127.23 33.57 28 19883 583 110568805
Neuralgia 126.56 33.57 89 19822 48389 110520999
Fatigue 124.36 33.57 33 19878 1215925 109353463
Incorrect route of product administration 121.27 33.57 97 19814 63964 110505424
Drug ineffective for unapproved indication 121.17 33.57 119 19792 102719 110466669
Septic shock 117.04 33.57 143 19768 157385 110412003
Hyperlactacidaemia 116.70 33.57 47 19864 8239 110561149
Acute kidney injury 110.39 33.57 306 19605 635124 109934264
Arthralgia 109.89 33.57 8 19903 779624 109789764
End stage renal disease 108.47 33.57 60 19851 21413 110547975
Diarrhoea 105.50 33.57 37 19874 1139468 109429920
Aortic stenosis 105.26 33.57 50 19861 13009 110556379
Diabetes mellitus 102.45 33.57 107 19804 99274 110470114
Dizziness 96.02 33.57 8 19903 698185 109871203
General physical health deterioration 95.74 33.57 226 19685 425069 110144319
Rash 94.48 33.57 17 19894 820947 109748441
Toxicity to various agents 93.01 33.57 241 19670 480314 110089074
Constipation 92.61 33.57 201 19710 357585 110211803
Pruritus 91.31 33.57 3 19908 581557 109987831
Peripheral ischaemia 91.16 33.57 43 19868 11015 110558373
Respiratory failure 89.33 33.57 148 19763 215184 110354204
Malaise 88.89 33.57 9 19902 671810 109897578
Pulseless electrical activity 87.88 33.57 48 19863 16709 110552679
Condition aggravated 83.65 33.57 306 19605 734530 109834858
Thrombosis 82.88 33.57 100 19811 108562 110460826
Headache 82.70 33.57 28 19883 882349 109687039
Haemodynamic instability 81.48 33.57 51 19860 22837 110546551
Gout 81.46 33.57 61 19850 36505 110532883
Chronic obstructive pulmonary disease 79.27 33.57 98 19813 109060 110460328
Blood calcium increased 79.22 33.57 46 19865 17994 110551394
Electrocardiogram QRS complex prolonged 78.71 33.57 41 19870 12980 110556408
Vitamin B1 increased 77.10 33.57 15 19896 165 110569223
Hyperlipidaemia 75.87 33.57 58 19853 35790 110533598
Intestinal ischaemia 75.71 33.57 43 19868 16136 110553252
Intentional product misuse 74.38 33.57 105 19806 132799 110436589
Abdominal pain 73.61 33.57 231 19680 512758 110056630
Total lung capacity decreased 69.08 33.57 31 19880 7083 110562305
Fall 68.28 33.57 13 19898 603469 109965919
Troponin increased 67.07 33.57 50 19861 29716 110539672
Hypoxia 64.73 33.57 97 19814 129418 110439970
Bacteroides infection 64.45 33.57 23 19888 2896 110566492
Dry gangrene 63.97 33.57 18 19893 1046 110568342
Dry mouth 61.87 33.57 121 19790 199827 110369561
Pain in extremity 60.71 33.57 8 19903 487110 110082278
Blood test abnormal 59.99 33.57 46 19865 28508 110540880
Disseminated intravascular coagulation 58.59 33.57 53 19858 41233 110528155
Somnolence 58.28 33.57 150 19761 297299 110272089
Bradycardia 56.71 33.57 101 19810 155416 110413972
Acidosis 55.63 33.57 40 19871 22491 110546897
Abdominal discomfort 55.52 33.57 4 19907 393854 110175534
Off label use 55.40 33.57 459 19452 1499726 109069662
Weight decreased 55.28 33.57 9 19902 468048 110101340
Blood cholesterol increased 54.96 33.57 110 19801 184675 110384713
Lung opacity 54.60 33.57 31 19880 11621 110557767
Back pain 54.59 33.57 3 19908 370993 110198395
Overdose 52.23 33.57 124 19787 233670 110335718
Weight increased 52.02 33.57 7 19904 419637 110149751
Peripheral swelling 51.89 33.57 6 19905 404028 110165360
Pain 51.24 33.57 58 19853 954897 109614491
Ulcer 50.94 33.57 50 19861 43066 110526322
Decreased appetite 50.22 33.57 12 19899 475834 110093554
Anion gap 49.02 33.57 17 19894 1968 110567420
Extremity necrosis 48.19 33.57 20 19891 3782 110565606
Renal injury 47.99 33.57 34 19877 18679 110550709
Ischaemia 47.57 33.57 26 19885 9057 110560331
Pulse absent 47.49 33.57 28 19883 11264 110558124
Pulmonary embolism 47.09 33.57 113 19798 214361 110355027
Infusion related reaction 45.74 33.57 7 19904 381155 110188233
Compartment syndrome 45.71 33.57 22 19889 5888 110563500
Urticaria 45.63 33.57 3 19908 318854 110250534
Hyperdynamic left ventricle 44.80 33.57 12 19899 580 110568808
Insomnia 44.72 33.57 6 19905 360584 110208804
Rhabdomyolysis 43.63 33.57 78 19833 120323 110449065
Serotonin syndrome 42.75 33.57 53 19858 59100 110510288
Infection 42.68 33.57 7 19904 362193 110207195
Asthenia 42.48 33.57 37 19874 688962 109880426
Hypoaesthesia 42.05 33.57 4 19907 314219 110255169
Heparin-induced thrombocytopenia 42.03 33.57 26 19885 11398 110557990
Respiratory depression 41.37 33.57 39 19872 31962 110537426
Renal failure 41.03 33.57 111 19800 226463 110342925
Pyrexia 40.54 33.57 62 19849 898203 109671185
Coagulopathy 40.27 33.57 43 19868 40868 110528520
Confusional state 40.26 33.57 17 19894 468663 110100725
Electrocardiogram abnormal 38.99 33.57 30 19881 18679 110550709
Paraesthesia 38.41 33.57 3 19908 276518 110292870
Product use in unapproved indication 37.73 33.57 170 19741 447207 110122181
Hypersensitivity 37.44 33.57 13 19898 403985 110165403
Chest pain 36.85 33.57 11 19900 376364 110193024
Gait disturbance 36.03 33.57 4 19907 278204 110291184
Aspartate aminotransferase increased 35.88 33.57 85 19826 159851 110409537
Congenital hiatus hernia 35.81 33.57 19 19892 6240 110563148
Ischaemic hepatitis 35.04 33.57 17 19894 4631 110564757
Blood creatinine increased 34.52 33.57 91 19820 182798 110386590

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01BA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA CS M0022562 Vasopressins
FDA PE N0000009908 Vasoconstriction
FDA PE N0000175360 Decreased Diuresis
MeSH PA D002317 Cardiovascular Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D014662 Vasoconstrictor Agents
MeSH PA D050034 Antidiuretic Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50248 hematologic agent
CHEBI has role CHEBI:52290 mitogen

Related Drugs by ATC class:

H01BA Vasopressin and analogues 4 drugs
desmopressinlypressinornipressinterlipressin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
von Willebrand disorder indication 128105004 DOID:12531
Hypotension with vasodilatory shock indication
Partial Central Diabetes Insipidus indication
Cardiac arrest off-label use 410429000 DOID:0060319
Uremic Bleeding Tendency off-label use
Chronic glomerulonephritis contraindication 20917003
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Uremia contraindication 44730006 DOID:4676
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Asthma contraindication 195967001 DOID:2841
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.19 acidic
pKa3 12.56 acidic
pKa4 12.85 acidic
pKa5 13.19 acidic
pKa6 13.43 acidic
pKa7 13.76 acidic
pKa8 10.75 Basic
pKa9 6.4 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200UNITS/10ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9937223 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PH HEALTH N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PH HEALTH N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
50UNITS/50ML (1UNITS/ML) VASOSTRICT PH HEALTH N204485 April 12, 2023 DISCN SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PH HEALTH N204485 April 15, 2020 DISCN SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vasopressin V1a receptor GPCR AGONIST Ki 9.59 CHEMBL CHEMBL
Vasopressin V1b receptor GPCR AGONIST Ki 9.31 CHEMBL CHEMBL
Vasopressin V2 receptor GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
Oxytocin receptor GPCR Ki 8.78 CHEMBL
Vasopressin V2 receptor GPCR IC50 8.48 CHEMBL
Oxytocin receptor GPCR Ki 8.93 CHEMBL
Vasopressin V2 receptor GPCR Ki 9.35 CHEMBL
Vasopressin V2 receptor GPCR Kd 8.82 CHEMBL
Vasopressin V1a receptor GPCR Kd 9.19 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.54 CHEMBL
Vasopressin V1 receptor GPCR Kd 9.19 CHEMBL

External reference:

IDSource
4018654 VUID
N0000179795 NUI
D00101 KEGG_DRUG
4018654 VANDF
C1705480 UMLSCUI
CHEBI:9937 CHEBI
CHEMBL373742 ChEMBL_ID
CHEMBL2108986 ChEMBL_ID
CHEMBL1201528 ChEMBL_ID
DB00067 DRUGBANK_ID
2168 IUPHAR_LIGAND_ID
1482 INN_ID
Y4907O6MFD UNII
644077 PUBCHEM_CID
1098 RXNORM
3144 MMSL
5667 MMSL
d00398 MMSL
002122 NDDF
002123 NDDF
002126 NDDF
005438 NDDF
005439 NDDF
126192003 SNOMEDCT_US
421078009 SNOMEDCT_US
772208008 SNOMEDCT_US
77671006 SNOMEDCT_US
C016671 MESH_SUPPLEMENTAL_RECORD_UI
Y4907O6MFD INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vasopressin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9640 INJECTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9647 INJECTION 40 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0517-1020 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0517-1030 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0548-9701 INJECTION 20 [USPU] INTRAVENOUS ANDA 24 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 25021-474 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS ANDA 25 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 51662-1682 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 16 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 51662-1688 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 16 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 63323-930 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS ANDA 25 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 65219-039 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS ANDA 25 sections
Vasopressin Human Prescription Drug Label 1 68083-520 INJECTION 20 [USPU] INTRAVENOUS ANDA 25 sections
Vasopressin Human Prescription Drug Label 1 68083-663 INJECTION 0.40 [USPU] INTRAVENOUS ANDA 25 sections
vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 70121-1642 INJECTION 20 [USPU] INTRAVENOUS ANDA 20 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 72572-860 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 81298-8552 SOLUTION 0.20 [USPU] INTRAVENOUS NDA 24 sections
Vasopressin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 81298-8554 SOLUTION 0.40 [USPU] INTRAVENOUS NDA 24 sections